Stock Research for GALT


Featured Broker: Ally Invest

Get the due diligence for another stock.


GALT Stock Chart & Research Data

The GALT chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the GALT chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


GALT Due diligence Resources & Stock Charts

The GALT stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View GALT Detailed Price Forecast - CNN Money CNN View GALT Detailed Summary - Google Finance
Yahoo View GALT Detailed Summary - Yahoo! Finance Zacks View GALT Stock Research & Analysis -

Stock Analysis

TradeIdeas View GALT Trends & Analysis - Trade-Ideas Barrons View GALT Major Holders - Barrons
NASDAQ View GALT Call Transcripts - NASDAQ Seeking View GALT Breaking News & Analysis - Seeking Alpha
Spotlight View GALT Annual Report - OTC Report View GALT OTC Short Report -
TradeKing View GALT Fundamentals - TradeKing Charts View GALT SEC Filings - Bar Chart
WSJ View Historical Prices for GALT - The WSJ Morningstar View Performance/Total Return for GALT - Morningstar
MarketWatch View the Analyst Estimates for GALT - MarketWatch CNBC View the Earnings History for GALT - CNBC
StockMarketWatch View the GALT Earnings - StockMarketWatch MacroAxis View GALT Buy or Sell Recommendations - MacroAxis
Bullish View the GALT Bullish Patterns - American Bulls Short Pains View GALT Short Pain Metrics -

Social Media Mentions

StockTwits View GALT Stock Mentions - StockTwits PennyStocks View GALT Stock Mentions - PennyStockTweets
Twitter View GALT Stock Mentions - Twitter Invest Hub View GALT Investment Forum News - Investor Hub
Yahoo View GALT Stock Mentions - Yahoo! Message Board Seeking Alpha View GALT Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for GALT - Insider Cow View Insider Transactions for GALT - Insider Cow
CNBC View GALT Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for GALT - OTC Markets
Yahoo View Insider Transactions for GALT - Yahoo! Finance NASDAQ View Institutional Holdings for GALT - NASDAQ

Stock Charts

FinViz View GALT Stock Insight & Charts - StockCharts View GALT Investment Charts -
BarChart View GALT Stock Overview & Charts - BarChart Trading View View GALT User Generated Charts - Trading View

Latest Financial News for GALT

Galectin's GR-MD-02 Positive in Phase Ib Study With Keytruda
Posted on Friday September 21, 2018

Galectin Therapeutics (GALT) posts favorable results from a phase Ib study on GR-MD-02 combined with Merck's Keytruda for treating metastatic melanoma.

Today's Research Reports on Trending Tickers: MiMedx Group and Galectin Therapeutics
Posted on Friday September 21, 2018

NEW YORK, NY / ACCESSWIRE / September 21, 2018 / Wall Street closed up on Thursday as upbeat economic data and strong corporate earnings helped buoy equities. Unemployment dropped by 3000 to a seasonally ...

Galectin stock lifts 15% premarket on early cancer combination trial results
Posted on Thursday September 20, 2018

Galectin Therapeutics Inc. shares surged 15% in Thursday premarket trade after the company said that combining its therapy, GR-MD-02, with Keytruda, Merck & Co.'s leading cancer therapy, appeared to have better results for patients with advanced melanoma than Keytruda alone. Notably, though, results were preliminary, based on data from an early-stage, phase 1b clinical trial, and integrated results from two earlier groups of patients on lower doses of GR-MD-02 with a third, higher-dose group. Galectin said that of 14 patients across the three groups, seven had reductions in cancer tumor size, or an objective response rate of 50%. Meanwhile, Keytruda alone has response rate that ranges between 21% to 39%, noted Dr. Brendan Curti, the trial's principal investigator and the director of the Providence Cancer Institute's melanoma program. Of the trial's 14 patients, nine had their cancer improve or remain stable, or a disease control rate of 64%. The phase 1b trial also enrolled six patients with head and neck cancer, for whom a 33% objective response rate and 67% disease control rate were observed. Curti said he and others were "very encouraged" by the melanoma results, and noted that results in both cancers were better than expected for Keytruda on its own. The trial will move forward in both areas, he said, and they plan to include more patients. Galectin shares have dropped nearly 24% over the last three months, compared with a 5.1% rise in the S&P 500 and a 7.1% rise in the Dow Jones Industrial Average .

Galectin Therapeutics, Inc. Announces Positive Preliminary Results from Phase 1b Clinical Trial of GR-MD-02 and KEYTRUDA® in Advanced Melanoma and Expansion of the Trial
Posted on Thursday September 20, 2018

Combination immunotherapy of GR-MD-02 and KEYTRUDA for all cohorts reported shows an Objective Response Rate of 50% (seven of fourteen patients). NORCROSS, Ga., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (GALT), the leading developer of therapeutics that target galectin proteins, and Providence Cancer Institute today announced additional preliminary clinical data from cohort 3 of an investigator-initiated Phase 1b clinical trial of GR-MD-02 used in combination with KEYTRUDA® (pembrolizumab) in patients with metastatic melanoma for which KEYTRUDA is indicated or those patients whose melanoma progressed during or recently after KEYTRUDA monotherapy.

Stock Market & Investing Books

Enter a stock symbol to view the stock details.